pasotuxizumab

English edit

From [Term?] +‎ -tu- (“tumor”) +‎ -xi- (“chimeric”) +‎ -zumab (“humanized monoclonal antibody”).

pasotuxizumab (uncountable)

(pharmacology) A bi-specific T-cell engager monoclonal antibody developed for the treatment of prostate cancer.
- 2021 May 26, Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu, “The landscape of bispecific T cell engager in cancer treatment”, in Biomarker Research, volume 9, →DOI, article 38, page 4:
  Pasotuxizumab (AMG 212) is a canonical BiTE antibody targeting PSMA [77]. The anti-tumor activity which was defined by PSA level decrease was dose-dependent. Two patients achieved long-term PSA responses with more than 1 year of treatment at doses of 40 μg/d and 80 μg/d, respectively.